文献速递炎症性肠病消化道肿瘤与早癌消化内镜

基于机器学习的移动应用CROHN'S AID用于结核流行区鉴别克罗恩病与肠结核的前瞻性验证

Development and Prospective Validation of a Machine Learning-Based Mobile Application (CROHN'S AID) for Differentiating Crohn's Disease From Intestinal Tuberculosis in Tuberculosis-Endemic Regions.
PubMed 文献 · Aliment Pharmacol Ther · 2026-09-21

前瞻性验证队列(n=121)中模型AUROC达0.921(0.870-0.963),优于标准贝叶斯参考标准(AUROC 0.750),最佳阈值下灵敏度和特异度分别为86.4%和85.5%。

要点

  • CROHN'S AID移动应用在结核流行区前瞻性验证中鉴别CD与ITB的AUROC为0.921。
  • 最佳阈值下灵敏度86.4%、特异度85.5%,优于标准贝叶斯参考标准。
  • 关键预测因子包括症状持续时间、横行溃疡、肉芽肿、直乙结肠受累和肛周病变。

核心结论

  • CROHN'S AID结合梯度提升决策树与智能手机技术,在资源有限地区有助于减少ITB与CD的误诊。

研究设计与样本

  • 领先模型CatBoost集成到移动应用,并在同一中心121例患者的前瞻性验证队列中验证。

主要发现

  • 内部交叉验证重复十次,CatBoost模型平均AUROC为0.886,平均灵敏度76.0%,特异度84.1%。
  • 前瞻性验证队列(n=121)中模型AUROC为0.921(0.870-0.963),优于标准贝叶斯参考标准(AUROC 0.750)。
  • 最佳阈值下模型灵敏度和特异度分别为86.4%和85.5%。
  • 关键预测因子包括症状持续时间、横行溃疡、肉芽肿、直乙结肠受累和肛周病变。

临床怎么用

  • 在结核流行区,CROHN'S AID可作为床旁实时临床决策支持工具,辅助鉴别克罗恩病与肠结核。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Differentiating Intestinal tuberculosis (ITB) from Crohn's disease is a major diagnostic challenge in endemic regions, often leading to inappropriate treatment. We aimed to develop and prospectively validate a machine learning-based mobile application, "Crohn's Aid", to provide an accurate, real-time clinical decision support tool at the point of care. METHODS: Retrospective analysis of a prospectively maintained database of 1066 patients (CD = 650; ITB = 416) from a tertiary centre in India. Thirty clinical, endoscopic and radiological variables were used to train multiple machine learning models, including CatBoost, Random forest and logistic regression. The lead model (CatBoost) was integrated into a mobile application. Performance was evaluated using area under the receiver operating characteristic (AUROC) and prospectively validated on a cohort of patients. Explainable AI (SHAP) values were used to identify key diagnostic drivers. The model was then validated on a prospective validation cohort of 121 patients at the same centre. RESULTS: Internal cross-validation was repeated ten times, and the CatBoost model achieved a mean AUROC of 0.886 with a mean sensitivity of 76.0% and specificity of 84.1%. In the prospective validation cohort (n = 121), the model maintained high diagnostic accuracy-AUROC 0.921(0.870-0.963) and outperformed the standard Bayesian reference standard (AUROC 0.750). At the optimum threshold, the model demonstrated a balanced sensitivity and specificity of 86.4% and 85.5%, respectively. Key predictors included symptom duration, transverse ulcers, granuloma, rectosigmoid involvement, and perianal disease. CONCLUSION: Crohn's Aid represents a step forward in the application of digital health to solve a long-standing clinical dilemma by combining the power of gradient-boosted decision trees with the ubiquity of smartphone technology to reduce misdiagnosis between ITB and CD in resource-limited settings.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Mohta S, Kutum R, Dhoundiyal A, et al. Development and Prospective Validation of a Machine Learning-Based Mobile Application (CROHN'S AID) for Differentiating Crohn's Disease From Intestinal Tuberculosis in Tuberculosis-Endemic Regions. Aliment Pharmacol Ther. 2026. PMID: 42768418. doi:10.1111/apt.70984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。